<SEC-DOCUMENT>0001817199-26-000010.txt : 20260302
<SEC-HEADER>0001817199-26-000010.hdr.sgml : 20260302
<ACCEPTANCE-DATETIME>20260302190528
ACCESSION NUMBER:		0001817199-26-000010
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20260302
FILED AS OF DATE:		20260302
DATE AS OF CHANGE:		20260302

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Ring Christine
		CENTRAL INDEX KEY:			0001817199
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39398
		FILM NUMBER:		26710259

	MAIL ADDRESS:	
		STREET 1:		C/O NURIX THERAPEUTICS, INC.
		STREET 2:		1700 OWENS STREET, SUITE 205
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nurix Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001549595
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				270838048
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1130

	BUSINESS ADDRESS:	
		STREET 1:		1600 SIERRA POINT PKWY
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		(415) 660-5320

	MAIL ADDRESS:	
		STREET 1:		1600 SIERRA POINT PKWY
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nurix, Inc.
		DATE OF NAME CHANGE:	20120509
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>wk-form4_1772496326.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2026-03-02</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001549595</issuerCik>
        <issuerName>Nurix Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>NRIX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001817199</rptOwnerCik>
            <rptOwnerName>Ring Christine</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O NURIX THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>1600 SIERRA POINT PKWY</rptOwnerStreet2>
            <rptOwnerCity>BRISBANE</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94005</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Legal Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>1</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2026-03-02</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>8148</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>15.4385</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>34601</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.</footnote>
        <footnote id="F2">Represents the weighted average sale price. The lowest price at which shares were sold was $15.16 and the highest price at which shares were sold was $15.845. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring</signatureName>
        <signatureDate>2026-03-02</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
